SCHEMBL12596161

SCHEMBL12596161

c1ccc(-c2ccc(N(c3ccc(-n4c5ccccc5c5ccccc54)cc3)c3c4ccccc4c(-c4ccccc4)c4ccccc34)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
ATM Q13315 1/20 0.47
KMT2A Q03164 3/20 0.40
HDAC4 P56524 1/20 0.40
IL1R1 P14778 1/20 0.35
MEN1 O00255 2/20 0.34
MAPT P10636 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.34
PTPN1 P18031 2/20 0.33
ACHE P22303 2/20 0.32
HTR7 P34969 1/20 0.32
TSPO P30536 1/20 0.32
MAPK8 P45983 1/20 0.32
RCE1 Q9Y256 1/20 0.32
EDNRB P24530 1/20 0.30
EDNRA P25101 1/20 0.30
AKR1C4 P17516 1/20 0.30
AKR1C3 P42330 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12596165 0.99 L3MBTL1 (0.46) KDM4EL3MBTL1ATMKMT2AHDAC4
SCHEMBL12596100 0.99 L3MBTL1 (0.46) KDM4EL3MBTL1ATMKMT2AHDAC4
SCHEMBL12893636 0.97 L3MBTL1 (0.45) KDM4EL3MBTL1ATMKMT2AHDAC4
SCHEMBL1262670 0.96 KDM4E (0.49) KDM4EL3MBTL1ATMKMT2AHDAC4
SCHEMBL12893606 0.94 KDM4E (0.47) KDM4EL3MBTL1ATMKMT2AHDAC4
SCHEMBL12596186 0.94 L3MBTL1 (0.53) KDM4EL3MBTL1ATMKMT2AHDAC4
SCHEMBL12894016 0.93 KDM4E (0.52) KDM4EL3MBTL1ATMKMT2AHDAC4
SCHEMBL12596042 0.92 L3MBTL1 (0.41) KDM4EL3MBTL1ATMKMT2AHDAC4
SCHEMBL17118522 0.91 KDM4E (0.40) KDM4EL3MBTL1ATMKMT2AHDAC4
SCHEMBL17118529 0.91 KDM4E (0.40) KDM4EL3MBTL1ATMKMT2AHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546792-B2 Anthracene derivative, and light emitting element, light emitting device, and electronic device using the anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-10-01 US disclosed
US-8546792-B2 Anthracene derivative, and light emitting element, light emitting device, and electronic device using the anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-10-01 US disclosed
US-20110121275-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, and Electronic Device Using the Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2011-05-26 US disclosed
US-7880019-B2 9-[N-phenyl-N-(9-phenylcarbazol-3-yl)amino]-10-phenylanthracene; high luminous efficiency; long lifetime SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-02-01 US disclosed
US-7880019-B2 9-[N-phenyl-N-(9-phenylcarbazol-3-yl)amino]-10-phenylanthracene; high luminous efficiency; long lifetime SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-02-01 US disclosed
US-20080086012-A1 Anthracene Derivative, And Light Emitting Element, Light Emitting Device, And Electronic Device Using the Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-04-10 US disclosed
US-20080086012-A1 Anthracene Derivative, And Light Emitting Element, Light Emitting Device, And Electronic Device Using the Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-04-10 US disclosed
WO-2008038607-A1 ANTHRACENE DERIVATIVE, AND LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE ANTHRACENE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080086012-A1 Anthracene Derivative, And Light Emitting Element, Light Emitting Device, And Electronic Device Using the Anthracene Derivative GLB1, CYP1A1, XPOT KDM4E 3720/4885L3MBTL1 716/4885ATM 1176/4885
US-20110121275-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, and Electronic Device Using the Anthracene Derivative GLB1, CYP1A1, XPOT KDM4E 3720/4885L3MBTL1 716/4885ATM 1176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.